Development of σ-receptor ligands and clinical trials

T. Nabeshima, I. Muraoka

研究成果: Review article査読

1 被引用数 (Scopus)

抄録

There are at least two classes of σ-receptors, termed σ1 and σ2. Recently, the σ1-receptor has been completely sequenced in different species. The amino acid sequences of the different purified proteins are highly homologous, but it shares no homology to know mammalian proteins. These results suggest that the σ1 receptor is a distinct entity from any often known receptors, σ-Receptors are involved in many physiological functions. Therefore, σ-ligands show many different pharmacological effects such as glucose utilization, neuroprotective, antipsychotic, antidepressive, anxiolytic, nootropic, antiepileptic, antiabuse, antitussive, antidiarrhea, anti-inflammatory, tear protein releasing stimulant and central anti- micturition reflex actions. These results suggest that σ-receptors are very promising targets for the development of new drugs that have new mechanisms of action.

本文言語English
ページ(範囲)3-11
ページ数9
ジャーナルFolia Pharmacologica Japonica
114
1
DOI
出版ステータスPublished - 1999

All Science Journal Classification (ASJC) codes

  • Pharmacology

フィンガープリント 「Development of σ-receptor ligands and clinical trials」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル